

2019 YEAR-IN-REVIEW

Plan sustainability: A powerful story

15.9%

Average savings for all first-year clients in 2019 (weighted)



62.9%

of clients experienced flat-lined or decreasing PMPMⁱ drug spend growth over last 3 years



Excluding SAⁱⁱ drugs, **68.6%**

of clients experienced flat-lined or decreasing PMPM drug spend growth over last 3 years



0.4%

Average inflation rate across all Reformulary employers in 2019



87.6%

Generic penetration rate (weighted)



85.4%

of claims for preferred drugs = members changing behaviours



29.8%

Percentage of specialty drug spend across all Reformulary employers in 2019



31.4%

Percentage of specialty drug spend in public and private plans representing 15.3 million Canadians



Preparing for the future = Understanding today



93

Pipeline drugs reviewed, monitored, and impact forecasted in 2019



92

New drugs with NOC evaluated by our Expert Committee in 2019

15.3 million Canadians / **1.5 billion** data records

Depth of our data lake. We clean, structure, mine, analyze, project, and apply machine learning to prescription claims data



Making sense of medical cannabis

Cannabis
standard

POWERED BY
REFORMULARY



Cannabis Standard™ recommendation platform
IN MARKET



Cannabis Standard™ Index
COMING MARCH 2020



Tools to measure your quality of life and productivity
COMING MARCH 2020

ⁱPer Member Per Month (PMPM)
ⁱⁱSpecial Authorization (SA)



NUMBERS VERIFIED BY ACTUARIES

Making sense of medicine

At Reformulary Group, we are committed to helping people make sense of medicine, through our prescription drug list, medical cannabis recommendation tool, and tools to help measure your quality of life and productivity.

Contact us today to learn more: Helen.Stevenson@reformulary.com

reformulary®
GROUP

